USPTO serial 97761835
ELXR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- DIBLE, JONATHON I
- Law office
- TMO LAW OFFICE 111 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with ELXR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John Paul Oleksiuk
JOHN PAUL OLEKSIUK COOLEY LLP1299 PENNSYLVANIA AVENUE, NW, SUITE 700WASHINGTON, DC 20004UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, pain, and also cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 3, 2023 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 2, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 2, 2023 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 14, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 26, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 24, 2023 | NWAP | NEW APPLICATION ENTERED | — |